|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CRACR2A |
Gene summary for CRACR2A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CRACR2A | Gene ID | 84766 |
| Gene name | calcium release activated channel regulator 2A | |
| Gene Alias | EFCAB4B | |
| Cytomap | 12p13.32 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q9BSW2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84766 | CRACR2A | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.24e-13 | -5.14e-01 | 0.0155 |
| 84766 | CRACR2A | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.52e-02 | -4.06e-01 | -0.1808 |
| 84766 | CRACR2A | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.26e-02 | -4.45e-01 | -0.1207 |
| 84766 | CRACR2A | HTA11_866_3004761011 | Human | Colorectum | AD | 9.92e-03 | -3.28e-01 | 0.096 |
| 84766 | CRACR2A | HTA11_10711_2000001011 | Human | Colorectum | AD | 3.04e-03 | -4.36e-01 | 0.0338 |
| 84766 | CRACR2A | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.85e-05 | -3.39e-01 | 0.0674 |
| 84766 | CRACR2A | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.14e-03 | -2.91e-01 | 0.294 |
| 84766 | CRACR2A | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 3.61e-08 | 1.28e+00 | 0.3487 |
| 84766 | CRACR2A | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.21e-02 | -3.27e-01 | 0.3859 |
| 84766 | CRACR2A | HTA11_99999973899_84307 | Human | Colorectum | MSS | 7.75e-05 | -5.52e-01 | 0.2585 |
| 84766 | CRACR2A | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.22e-11 | -4.77e-01 | 0.3005 |
| 84766 | CRACR2A | F007 | Human | Colorectum | FAP | 1.77e-05 | -3.97e-01 | 0.1176 |
| 84766 | CRACR2A | A002-C-010 | Human | Colorectum | FAP | 2.16e-03 | -2.05e-01 | 0.242 |
| 84766 | CRACR2A | A001-C-207 | Human | Colorectum | FAP | 2.80e-04 | -1.75e-01 | 0.1278 |
| 84766 | CRACR2A | A015-C-203 | Human | Colorectum | FAP | 1.88e-21 | -1.58e-01 | -0.1294 |
| 84766 | CRACR2A | A015-C-204 | Human | Colorectum | FAP | 9.08e-05 | -2.24e-01 | -0.0228 |
| 84766 | CRACR2A | A014-C-040 | Human | Colorectum | FAP | 2.15e-02 | -1.72e-01 | -0.1184 |
| 84766 | CRACR2A | A002-C-201 | Human | Colorectum | FAP | 2.62e-13 | -2.08e-01 | 0.0324 |
| 84766 | CRACR2A | A002-C-203 | Human | Colorectum | FAP | 9.15e-04 | -2.13e-01 | 0.2786 |
| 84766 | CRACR2A | A001-C-119 | Human | Colorectum | FAP | 7.10e-08 | -2.59e-01 | -0.1557 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0051403 | Colorectum | AD | stress-activated MAPK cascade | 72/3918 | 239/18723 | 4.77e-04 | 5.25e-03 | 72 |
| GO:0031098 | Colorectum | AD | stress-activated protein kinase signaling cascade | 74/3918 | 247/18723 | 4.80e-04 | 5.27e-03 | 74 |
| GO:0070302 | Colorectum | AD | regulation of stress-activated protein kinase signaling cascade | 58/3918 | 195/18723 | 2.21e-03 | 1.74e-02 | 58 |
| GO:0032872 | Colorectum | AD | regulation of stress-activated MAPK cascade | 57/3918 | 192/18723 | 2.51e-03 | 1.92e-02 | 57 |
| GO:0032411 | Colorectum | AD | positive regulation of transporter activity | 37/3918 | 120/18723 | 6.82e-03 | 4.22e-02 | 37 |
| GO:00324111 | Colorectum | SER | positive regulation of transporter activity | 31/2897 | 120/18723 | 2.25e-03 | 2.16e-02 | 31 |
| GO:00310981 | Colorectum | SER | stress-activated protein kinase signaling cascade | 54/2897 | 247/18723 | 4.65e-03 | 3.67e-02 | 54 |
| GO:0032409 | Colorectum | SER | regulation of transporter activity | 65/2897 | 310/18723 | 5.71e-03 | 4.19e-02 | 65 |
| GO:00514031 | Colorectum | SER | stress-activated MAPK cascade | 52/2897 | 239/18723 | 5.96e-03 | 4.35e-02 | 52 |
| GO:00310982 | Colorectum | MSS | stress-activated protein kinase signaling cascade | 67/3467 | 247/18723 | 5.28e-04 | 5.99e-03 | 67 |
| GO:00514032 | Colorectum | MSS | stress-activated MAPK cascade | 65/3467 | 239/18723 | 5.87e-04 | 6.49e-03 | 65 |
| GO:00324091 | Colorectum | MSS | regulation of transporter activity | 78/3467 | 310/18723 | 2.09e-03 | 1.78e-02 | 78 |
| GO:0034764 | Colorectum | MSS | positive regulation of transmembrane transport | 58/3467 | 219/18723 | 2.19e-03 | 1.83e-02 | 58 |
| GO:00324112 | Colorectum | MSS | positive regulation of transporter activity | 35/3467 | 120/18723 | 2.95e-03 | 2.28e-02 | 35 |
| GO:00703021 | Colorectum | MSS | regulation of stress-activated protein kinase signaling cascade | 52/3467 | 195/18723 | 3.07e-03 | 2.34e-02 | 52 |
| GO:0022898 | Colorectum | MSS | regulation of transmembrane transporter activity | 70/3467 | 278/18723 | 3.36e-03 | 2.54e-02 | 70 |
| GO:00328721 | Colorectum | MSS | regulation of stress-activated MAPK cascade | 51/3467 | 192/18723 | 3.65e-03 | 2.69e-02 | 51 |
| GO:0032412 | Colorectum | MSS | regulation of ion transmembrane transporter activity | 66/3467 | 267/18723 | 6.72e-03 | 4.38e-02 | 66 |
| GO:00310983 | Colorectum | FAP | stress-activated protein kinase signaling cascade | 61/2622 | 247/18723 | 4.79e-06 | 1.57e-04 | 61 |
| GO:00514033 | Colorectum | FAP | stress-activated MAPK cascade | 59/2622 | 239/18723 | 6.90e-06 | 2.11e-04 | 59 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CRACR2A | SNV | Missense_Mutation | novel | c.1930N>A | p.Glu644Lys | p.E644K | Q9BSW2 | protein_coding | tolerated(0.14) | benign(0.068) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CRACR2A | SNV | Missense_Mutation | c.773N>A | p.Arg258Lys | p.R258K | Q9BSW2 | protein_coding | tolerated(0.19) | probably_damaging(0.987) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| CRACR2A | insertion | Nonsense_Mutation | novel | c.720_721insCCAAGGTAAGCAGGATCCTTCTGGAAACATGTTCATAAAACT | p.Met240_Glu241insProArgTerAlaGlySerPheTrpLysHisValHisLysThr | p.M240_E241insPR*AGSFWKHVHKT | Q9BSW2 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| CRACR2A | insertion | In_Frame_Ins | novel | c.1004_1005insTGACTGTGGTCGTGTAGAGACCTGGGAGGCCAA | p.Ser335_Leu336insAspCysGlyArgValGluThrTrpGluAlaAsn | p.S335_L336insDCGRVETWEAN | Q9BSW2 | protein_coding | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CRACR2A | insertion | Nonsense_Mutation | novel | c.924_925insTCTGACTGCTGGCAGGATTTTGGTCCATAGGCCTAAATA | p.Leu308_Lys309insSerAspCysTrpGlnAspPheGlyProTerAlaTerIle | p.L308_K309insSDCWQDFGP*A*I | Q9BSW2 | protein_coding | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| CRACR2A | SNV | Missense_Mutation | rs563950130 | c.1705N>T | p.Arg569Trp | p.R569W | Q9BSW2 | protein_coding | deleterious(0) | possibly_damaging(0.736) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CRACR2A | SNV | Missense_Mutation | rs758305378 | c.1823G>A | p.Arg608Gln | p.R608Q | Q9BSW2 | protein_coding | tolerated(0.06) | probably_damaging(0.963) | TCGA-C5-A7CK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| CRACR2A | SNV | Missense_Mutation | novel | c.1486G>A | p.Glu496Lys | p.E496K | Q9BSW2 | protein_coding | tolerated(0.08) | benign(0.391) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CRACR2A | SNV | Missense_Mutation | c.600N>A | p.Phe200Leu | p.F200L | Q9BSW2 | protein_coding | tolerated(0.2) | benign(0.015) | TCGA-EK-A2RO-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CRACR2A | SNV | Missense_Mutation | c.1004N>A | p.Ser335Asn | p.S335N | Q9BSW2 | protein_coding | tolerated(0.34) | benign(0.219) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |